FBLIM1: A Drug Target / Disease Biomarker (G54751)

Target Name: FBLIM1

NCBI ID: G54751

FBLIM1

FBLIM1: A Drug Target / Disease Biomarker

FBLIM1, also known as FBL-001, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the FBL family of proteins, which are known for their role in cell-signaling pathways. FBLIM1 has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of FBLIM1 is its ability to interact with various signaling pathways. FBLIM1 has been shown to play a role in several signaling pathways that are involved in cell growth, survival, and angiogenesis. For example, FBLIM1 has been shown to be involved in theNotch signaling pathway, which is involved in the development and maintenance of tissues throughout the body.

FBLIM1 has also been shown to be involved in the TGF-β signaling pathway, which is involved in cell growth, differentiation, and survival. This is important because TGF-β is a well-established risk factor for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another promising aspect of FBLIM1 is its ability to interact with various proteins that are involved in cell signaling. FBLIM1 has been shown to interact with several proteins, including FGFR1, TGDF2, and PDGFR-尾. These proteins are involved in several different signaling pathways, including signaling pathways that are involved in cell growth, differentiation, and survival.

FBLIM1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. For example, FBLIM1 has been shown to be involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues throughout the body.

In addition to its role in several signaling pathways, FBLIM1 has also been shown to have several potential therapeutic applications. For example, FBLIM1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that FBLIM1 may be a useful target for therapies that are aimed at treating these conditions.

FBLIM1 has also been shown to be involved in the development of certain types of cancer, including breast cancer and colorectal cancer. This suggests that FBLIM1 may be a useful target for therapies that are aimed at treating these conditions.

In addition to its potential therapeutic applications, FBLIM1 is also of interest as a potential biomarker. This is because FBLIM1 has been shown to be expressed in a variety of tissues and cells, including brain, heart, and kidney cells. This suggests that FBLIM1 may be a useful biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, FBLIM1 is a protein that has significant potential as a drug target or biomarker. Its ability to interact with multiple signaling pathways and to play a role in several cellular processes that are important for maintaining tissue homeostasis makes it an attractive target for therapies that are aimed at treating a variety of diseases. Further research is needed to fully understand the role of FBLIM1 in these processes and to develop effective therapies.

Protein Name: Filamin Binding LIM Protein 1

Functions: Serves as an anchoring site for cell-ECM adhesion proteins and filamin-containing actin filaments. Is implicated in cell shape modulation (spreading) and motility. May participate in the regulation of filamin-mediated cross-linking and stabilization of actin filaments. May also regulate the assembly of filamin-containing signaling complexes that control actin assembly. Promotes dissociation of FLNA from ITGB3 and ITGB7. Promotes activation of integrins and regulates integrin-mediated cell-cell adhesion

The "FBLIM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBLIM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets